Since Annex II to Regulation (EU) 2019/6, as replaced by Commission Delegated Regulation (EU) 2021/805 [Commission Delegated Regulation (EU) 2021/805 of 8 March 2021 amending Annex II to Regulation (EU) 2019/6 of the European Parliament and of the Council (OJ L 180, 21.5.2021, p. 3).] has applied since 28 January 2022, this Regulation should also apply from that date in order to avoid unnecessary repetition of pharmacological, toxicological, residue and pre-clinical safety studies conducted with respect to applications for marketing authorisations submitted before the entry into force of this Regulation.
Recital 3, Regulation (EU) 2023/183
In forcesince 23 Nov 2022